May 24, 2011
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
FDA clears molecular MRSA test
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The FDA has granted clearance for an automated molecular test for screening methicillin-resistant Staphylococcus aureus, according to a press release.
BioMerieux announced that its NucliSENS EasyQ test received clearance after achieving clinical sensitivity of 94.7% and clinical specificity of 96.5% when testing nasal samples of adult patients. The sensitivity was 100% and the specificity was 97.3% for nasal samples from children.
The test detects seven of the most common MRSA strains by simultaneously detecting two targets. The system has the capacity to support batch processing of up to 46 MRSA screening tests in a compact space within a 3-hour period.
 |
Follow InfectiousDiseaseNews.com on Twitter. |